These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28264052)

  • 1. Restless legs syndrome augmentation among Japanese patients receiving pramipexole therapy: Rate and risk factors in a retrospective study.
    Takahashi M; Nishida S; Nakamura M; Kobayashi M; Matsui K; Ito E; Usui A; Inoue Y
    PLoS One; 2017; 12(3):e0173535. PubMed ID: 28264052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation in patients with restless legs syndrome receiving pramipexole therapy: a retrospective study in a single center from China.
    Wang T; Ying M; Zhao R; Zhu D; Zhang L
    Sleep Breath; 2022 Mar; 26(1):373-380. PubMed ID: 33864178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial.
    Bassetti CL; Bornatico F; Fuhr P; Schwander J; Kallweit U; Mathis J;
    Swiss Med Wkly; 2011; 141():w13274. PubMed ID: 22101745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term open-label study of pramipexole in patients with primary restless legs syndrome.
    Inoue Y; Kuroda K; Hirata K; Uchimura N; Kagimura T; Shimizu T
    J Neurol Sci; 2010 Jul; 294(1-2):62-6. PubMed ID: 20451927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pregabalin with pramipexole for restless legs syndrome.
    Allen RP; Chen C; Garcia-Borreguero D; Polo O; DuBrava S; Miceli J; Knapp L; Winkelman JW
    N Engl J Med; 2014 Feb; 370(7):621-31. PubMed ID: 24521108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease.
    Maestri M; Fulda S; Ferini-Strambi L; Zucconi M; Marelli S; Staedler C; Bassetti CL; Manconi M
    Sleep Med; 2014 May; 15(5):570-5. PubMed ID: 24767724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
    Geyer J; Bogan R
    Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample.
    Allen RP; Ondo WG; Ball E; Calloway MO; Manjunath R; Higbie RL; Lee MR; Nisbet PA
    Sleep Med; 2011 May; 12(5):431-9. PubMed ID: 21493132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term use of pramipexole in the management of restless legs syndrome.
    Lipford MC; Silber MH
    Sleep Med; 2012 Dec; 13(10):1280-5. PubMed ID: 23036265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS).
    Winkelman JW; Johnston L
    Sleep Med; 2004 Jan; 5(1):9-14. PubMed ID: 14725821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pramipexole in the management of restless legs syndrome: an extended study.
    Silber MH; Girish M; Izurieta R
    Sleep; 2003 Nov; 26(7):819-21. PubMed ID: 14655914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
    García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
    Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance.
    Jama L; Hirvonen K; Partinen M; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
    Sleep Med; 2009 Jun; 10(6):630-6. PubMed ID: 19171500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole (Mirapex) for restless legs syndrome.
    Med Lett Drugs Ther; 2007 Mar; 49(1257):26-8. PubMed ID: 17375031
    [No Abstract]   [Full Text] [Related]  

  • 15. Compulsive habits in restless legs syndrome patients under dopaminergic treatment.
    Pourcher E; Rémillard S; Cohen H
    J Neurol Sci; 2010 Mar; 290(1-2):52-6. PubMed ID: 19969309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model.
    Luo F; Li C; Ondo WG; Xu P; Xie W; Le W
    Sleep Med; 2011 Jan; 12(1):41-6. PubMed ID: 21044864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.
    Trenkwalder C; Stiasny-Kolster K; Kupsch A; Oertel WH; Koester J; Reess J
    Mov Disord; 2006 Sep; 21(9):1404-10. PubMed ID: 16755554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of exercise and pramipexole in the treatment of restless leg syndrome: Implications on the dopaminergic system and PTPRD.
    Morais MA; Franco B; Holanda ASS; Simino LAP; Manconi M; Torsoni A; Esteves AM
    Sleep Med; 2023 Oct; 110():201-211. PubMed ID: 37633178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study.
    Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
    Sleep Med; 2006 Aug; 7(5):407-17. PubMed ID: 16815748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramipexole: in restless legs syndrome.
    McCormack PL; Siddiqui MA
    CNS Drugs; 2007; 21(5):429-37; discussion 438-40. PubMed ID: 17447832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.